Developing new drugs and therapies is a contact sport for research sites. Investigators are on the frontlines, meeting and ...

As the European Society of Cardiology Congress 2026 kicks off today, UK biopharma company Isomab has presented landmark ...

Sword Health, a digital therapeutics company that started in the physical therapy space, has acquired digital mental health ...

The FDA issued approvals for Pfizer and Moderna's 2026 COVID-19 vaccines on Thursday, but is recommending them for the same ...

After a series of bumps in the road, Roviant and Priovant Therapeutics have finally secured US approval for the once-daily oral TYK2/JAK1 inhibitor, Lisraya (brepocitinib), for adults with ...

The MHS technology is Anthropic’s first tool designed to operate in the physical world. According to the Financial Times, ...

Pharmaceutical portfolio decision-making is facing structural pressure. Patent expirations, rising development costs, ...

Medical technology company Boston Scientific became the target of a cyberattack this week, which disrupted some of its IT ...

The US FDA has green lit ViiV Healthcare’s Tivicay PD (dolutegravir) for the treatment of HIV-1 in children weighing at least ...

The Marcus Evans AI, Forecasting, Insights and Analytics for Smarter Decisions in Pharma conference will explore how pharma ...

The ambition to build a Phase I oncology clinical development centre can be deceptively simple. The temptation is to ...

AstraZeneca and Amgen have announced the first Phase III results for Tezspire (tezepelumab) in eosinophilic oesophagitis (EoE ...